Related Experiment Video
Updated: May 23, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Do bisphosphonates slow the progression of aortic stenosis?
Olcay Aksoy1, Akin Cam, Sachin S Goel
1Department of Cardiovascular Medicine, Cleveland Clinic, Ohio 44195, USA.
Journal of the American College of Cardiology
|April 14, 2012
Summary
Bisphosphonates did not significantly alter the progression of aortic stenosis in older women. This study found no impact on aortic valve area, gradients, survival, or need for valve replacement.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Geriatrics
Background:
- Valvular calcification is a key factor in aortic stenosis development and progression.
- Bisphosphonates are hypothesized to potentially slow the progression of aortic stenosis.
Purpose of the Study:
- To evaluate the effect of bisphosphonates on the progression of aortic stenosis.
- To determine if bisphosphonates influence hemodynamic changes or clinical outcomes in patients with aortic stenosis.
Main Methods:
- Retrospective analysis of 801 female patients aged over 60 with moderate aortic stenosis.
- Inclusion criteria required follow-up echocardiograms at least one year apart.
- Propensity-matching was used to compare patients on bisphosphonates versus those not.
Main Results:
- No significant difference in the rate of change in aortic valve area or gradients between bisphosphonate users and non-users.
- Bisphosphonate use did not affect patient survival rates.
- No impact on freedom from the need for aortic valve replacement was observed.
Conclusions:
- Bisphosphonates do not appear to significantly impact the hemodynamic progression of aortic stenosis.
- The use of bisphosphonates showed no significant effect on clinical outcomes in this patient cohort.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...